Opinion

Video

Individualizing Therapy Goals for Patients With Myelofibrosis

Author(s):

Andrew Kuykendall, MD,Raajit K. Rampal, MD, PhD

Andrew Kuykendall, MD, emphasizes the importance of individualizing therapy for patients with myelofibrosis, focusing on improving quality of life and addressing specific issues like anemia and spleen volume, with the understanding that these treatments are palliative and goals should be revisited regularly.

Related Videos
Phase 3 AMPLIFY Trial
Guillermo Garcia-Manero, MD
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, highlight key data in CML and ALL presented at the 2024 ASH Annual Meeting.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, detail factors for selecting a TKI in later lines of therapy in chronic myeloid leukemia.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss data for ponatinib plus chemotherapy in Ph-positive ALL.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss dosing strategies for ponatinib in CML and ALL.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the mutational analysis for ponatinib in the OPTIC trial in CP-CML.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss 5-year data for ponatinib in pretreated CP-CML.
Christiane Querfeld, M.D., Ph.D
Naval G. Daver, MD,
Related Content
Hematology | Image credit: © Nittaya – stock.adobe.com
January 29th 2025

Second Primary Cancer Risk Informs the Risk-Benefit Profile of CAR T-Cell Therapies

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital
November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

Ashkan Emadi, MD
January 27th 2025

Venetoclax/Pegcrisantaspase Combo Offers Potential to Overcome Venetoclax Resistance in R/R AML

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

FDA
January 24th 2025

FDA Approves Treosulfan for alloHCT Conditioning in AML and MDS

Acute Myeloid Leukemia | stock.adobe.com
January 23rd 2025

Maintenance Galinpepimut-S Appears Effective and Safe in AML in Second CR